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Background: In contrast to pediatric Crohn’s disease (CD), little is known in pediatric ulcerative colitis (UC) about the relationship between 
disease phenotype and serologic reactivity to microbial and other antigens.
Aim: The aim of this study was to examine disease phenotype and serology in a well-characterized inception cohort of children newly diagnosed 
with UC during the PROTECT Study (Predicting Response to Standardized Pediatric Colitis Therapy).
Methods: Patients were recruited from 29 participating centers. Demographic, clinical, laboratory, and serologic (pANCA, ASCA IgA/IgG, 
Anti-CBir1, and Anti-OmpC) data were obtained from children 4–17 years old with UC.
Results: Sixty-five percent of the patients had positive serology for pANCA, with 62% less than 12 years old and 66% 12 years old or older. 
Perinuclear anti-neutrophil cytoplasmic antibodies did not correspond to a specific phenotype though pANCA ≥100, found in 19%, was strongly 
associated with pancolitis (P = 0.003). Anti-CBir1 was positive in 19% and more common in younger children with 32% less than 12 years old as 
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compared with 14% 12 years old or older (P < 0.001). No association was found in any age group between pANCA and Anti-CBir1. Relative rectal 
sparing was more common in +CBir1, 16% versus 7% (P = 0.02). Calprotectin was lower in Anti-CBir1+ (Median [IQR] 1495 mcg/g [973–3333] vs 
2648 mcg/g [1343–4038]; P = 0.04). Vitamin D 25-OH sufficiency was associated with Anti-CBir1+ (P = 0.0009).
Conclusions: The frequency of pANCA in children was consistent with adult observations. High titer pANCA was associated with more exten-
sive disease, supporting the idea that the magnitude of immune reactivity may reflect disease severity. Anti-CBir1+ was more common in younger 
ages, suggesting host-microbial interactions may differ by patient age.
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INTRODUCTION
Ulcerative colitis (UC) denotes a phenotype of chronic 
inflammatory bowel disease (IBD) in which inflammation is 
localized to the mucosa and extends proximally from the rectum 
to varying extents of the large intestine. It is thought to result in 
genetically susceptible individuals, from an inappropriate activa-
tion of the immune system and intestinal dysbiosis at the mucosal 
luminal interface1. UC is remarkably heterogeneous with respect 
to age of onset, anatomical extent, disease course, and response 
to therapies2–6; in general, children have a more severe clinical 
phenotype than adults with more extensive disease and a greater 
early need for corticosteroids and biologic therapies7, 8.
The heterogeneity of IBD has prompted a search for a 
marker or combination of markers to distinguish IBD from 
non-IBD, differentiate IBD subtypes (UC versus CD), antici-
pate disease outcomes, and predict response to therapies. 
A number of studies from the early 1990s onward have eval-
uated various serological immune markers to fill this role9–12. 
Perinuclear anti-neutrophil cytoplasmic antibody (pANCA) 
has historically been linked to a UC phenotype, and anti-sac-
charomyces cerevisiae antibody (ASCA) has been associated 
with a classic CD behavior. Anti-flagellin (Anti-CBir1) reactiv-
ity, on the other hand, has been described to be more prevalent 
in younger-onset CD, characterized by a colitis phenotype13, 
but its prevalence in pediatric UC remains undefined.
The PROTECT Study (Predicting Response to 
Standardized Pediatric Colitis Therapy) was initiated in 2012 
to systematically examine treatment responses of children and 
adolescents newly diagnosed with UC. This multicenter incep-
tion cohort was designed to examine the demographic, clinical, 
laboratory, endoscopic, histologic, and serologic factors that are 
associated with initial response to therapy. This study tests the 
hypothesis that serologic reactivity is related to disease pheno-
type, histology, and laboratory values in children with newly 
diagnosed UC. While this relationship has been studied thor-
oughly in pediatric CD, the same rigorous studies do not exist 
in pediatric UC, and an improved understanding of the preva-
lence and associations with these serologic markers would better 
inform diagnosis, disease classification, and, potentially, therapy.
MATERIALS AND METHODS
Patient Population
Potential study patients were recruited from the clinical 
practices of the 29 centers participating in PROTECT. Children 
between the ages of 4 and 17 years inclusive with a clinical his-
tory consistent with colonic inflammation (eg, any combination 
of diarrhea, bleeding, abdominal pain) were eligible for study. 
Complete demographic, clinical, laboratory, and serologic data 
were obtained along with diagnostic esophagogastroduodeno-
scopy and ileocolonoscopy. Eligibility required disease extent 
beyond the rectum, a baseline Pediatric Ulcerative Colitis 
Activity Index (PUCAI) 14 score of ≥10, no previous therapy for 
colitis, and a stool culture negative for enteric bacterial path-
ogens (Salmonella, Shigella, Campylobacter, E. coli 0157:H7) 
and Clostridium difficile toxin. Patients were all newly diag-
nosed with UC, and this was a clinical, endoscopic, and his-
tologic diagnosis of UC using previously established criteria. 
Exclusionary criteria included any clinical, endoscopic, radio-
logic, or histologic evidence of CD.
Age
Age was evaluated by years in categories of 4–6, 7–10, 
11–13, and 14–17  years old to assess trends in seropositivity 
across childhood and adolescence.
Clinical Disease Activity
Clinical activity was determined by the PUCAI (range 
0–85) and endoscopic activity by the Mayo endoscopy sub-
score 15. PUCAI <10 denoted inactive disease/remission, 10–34 
denoted mild, 35–64 denoted moderate, and ≥65 denoted severe 
disease. The baseline PUCAI was defined as the last PUCAI 
on or before the treatment start date, and the majority (>60%) 
occurred on the scope date itself.
Endoscopic Assessment
Endoscopic evaluation included assessment of mucosal 
inflammation noting granularity, loss of vascular pattern, small 
superficial ulcers, mucopurulent exudate, and a line of demar-
cation between abnormal and normal colon in a patient whose 
colitis did not extend to the cecum. Note was made whether 
there was patchiness to the endoscopic appearance or relative 
rectal sparing.
Disease Extent
Disease extent was classified as proctosigmoiditis, left-
sided colitis (to the splenic flexure), extensive colitis (to the 
hepatic flexure), and pancolitis (to the cecum). In analyses, we 
combined extensive colitis, pancolitis, and cases where a limited 
examination was performed due to severity of disease. Visual 
evidence of inflammation, not histology, was used to determine 
disease extent.
Histology
Centralized histologic examination was performed on 
a single rectal biopsy by one of the authors (MC) who was 
blinded to clinical data via a standardized scoring system that 
was created for PROTECT to evaluate degree of inflammation 
and architectural changes, and this scoring system has been 
previously published16. Of note, chronic features were scored 
as either present or absent, and these included ulcer/erosion, 
surface villiform changes, basal plasmacytosis, basal lymphoid 
aggregates, Paneth cell metaplasia, and crypt architectural 
abnormalities.
Laboratory Assessment
Hemoglobin (Hgb), hematocrit (Hct), white blood cell 
count (WBC), serum albumin, erythrocyte sedimentation rate 
(ESR), and C-reactive protein (CRP) were recorded from local 
site standard-of-care assessments, as available, within 4 weeks 
prior to initial UC treatment and not more than 2 days after 
initiating treatment. For some sites, the standard of care for 
milder disease did not include laboratory studies before a col-
onoscopy, and so the baseline window for participants with a 
mild PUCAI was extended to 8 weeks. Plasma albumin was 
measured at a central laboratory by ELISA per manufacturer’s 
instructions (Cell Biolabs, Inc., San Diego, CA) for participants 
with no available local serum value. We report observed val-
ues of all laboratory studies with the exception of C-reactive 
protein, which we report with respect to the upper limit of 
normal (ULN) for the local laboratory. Fecal calprotectin was 
determined using an ELISA (Bühlmann Laboratories AG, 
Schönenbuch, Switzerland) from stool samples collected before 
colonoscopy cleanout or at least 2 days after colonoscopy, but 
not more than 3 days after initial UC treatment 17, 18. Vitamin 
D 25-OH was performed centrally from plasma collected at 
baseline, and the level was defined as “sufficient” (≥30 ng/mL), 
“insufficient” (20-<30 ng/mL), or “deficient” (<20 ng/mL) 19.
Serology
Serologic determination of pANCA, ASCA IgG and IgA, 
Anti-CBir1, and anti-outer membrane C (Anti-OmpC) was 
performed at Cedars-Sinai Hospital, Los Angeles, California, 
utilizing previously published methods20. Perinuclear anti-neu-
trophil cytoplasmic antibody was considered high-titer at a 
level of ≥100 EU/mL21–23. 
Statistical Analysis
Demographic, clinical, and serologic characteristics 
were compared across age categories: 4–6, 7–10, 11–13, and 
14–17 years old. Patients were grouped as pANCA positive ver-
sus negative, pANCA titer negative versus positive, <100 versus 
positive and ≥100, and Anti-CBir1 positive versus negative. 
Groups were compared using a χ2 test or Fisher exact test for 
categorical assessments, a Mantel-Haenszel χ2 test for ordinal 
categorical assessments, a t test for normally distributed con-
tinuous assessments, and a Wilcoxon rank-sum test for con-
tinuous assessments with skewed distributions. Age-adjusted 
least-squares-mean titer values by disease location were 
obtained by analysis of covariance. All statistical tests were 
2-tailed. There was no adjustment for multiple comparisons;
P values are for descriptive purposes. Analyses were conducted
using SAS version 9.3 (SAS Institute, Cary, NC).
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A total of 431 subjects were confirmed to have UC, and 
399 (93%) had serology performed. Baseline demographic, clin-
ical, and laboratory characteristics—categorized by age—of 
the 399 patients are shown in Table 1.
Serologic Immune Markers
Perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA)
Perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA) was positive in 65% (260 of 399)  of patients. The 
percentage of pANCA positive was lower in ages 4–6 (44%, 11 
of 25) than ages 7–17 (67%, 249/ of 34; P = 0.022) (See Fig. 1). 
The prevalence of pANCA was comparable across the other 
age groups: 7–10 (69%), 11–13 (63%), and 14–17 (68%) years 
old (P = 0.63). Positive pANCA did not correspond to a spe-
cific phenotype, (ie, there was no significant difference in extent 
of disease, PUCAI, Mayo score, rectal sparing, or basal plas-
macytosis) (Table 2). However, average age-adjusted pANCA 
titer was somewhat higher for extensive pancolitis (least squares 
mean 60.0; 95% CI, 55.3–64.7) compared with proctosigmoid-
itis (39.2; 95% CI:,21.7–56.7) and left-sided disease (48.1; 95% 
CI, 34.4–61.5; P = 0.028). A pANCA titer ≥100, as observed 
in 19% of the patients, was strongly associated with pancolitis. 
All but 3 of the 76 (96%) with pANCA ≥100 had extensive col-
itis, as compared with 81% of the remaining 324 with pANCA 
<100 (P = 0.001) and 83% of the 139 who were pANCA neg-
ative (P = 0.005). However, the PUCAI and Mayo endoscopy 
subscores were not significantly different between groups with 
pANCA ≥100 and pANCA <100.
Anti-flagellin (Anti-CBir1)
Anti-CBir1 was positive in 19% (77 of 399) of patients 
and more commonly positive in younger children. The per-
centage of Anti-CBir1 positive decreased steadily with age 
(Spearman rank correlation = −0.25, P < 0.001), with the high-
est in ages 4–6 (44%) and lowest in ages 14–17 (10%) (Fig. 1). 
Table 3 characterizes the associations of Anti-CBir1 with phe-
notype and baseline laboratory studies. More limited disease 
(proctosigmoiditis or left-sided colitis) was more common in 
Anti-CBir1-negative patients (18% vs 9%, P = 0.041). However, 
relative rectal sparing was more common in Anti-CBir1-positive 
patients (16% vs 7 %, P = 0.023), and basal plasmacytosis on 
rectal biopsy was less common (38% vs 56% P = 0.016). There 
was no association between pANCA and Anti-CBir1 in any 
age group.
Fecal calprotectin was higher in the Anti-CBir1-negative 
group (median: 2634 mcg/g, interquartile range [IQR]: 
1324–4022]) compared with the Anti-CBir1-positive group 
(median: 1495 mcg/g [IQR: 973–3333], P = 0.046), despite sim-
ilar Mayo endoscopy subscores, ESR, and CRP. Additionally, 
both the median 25-OH vitamin D level (P = 0.0002) and the 
percentage of patients with sufficient levels of 25-OH vitamin 
D (P = 0.0009) were strikingly higher in the Anti-CBir1-positive 
group. This relationship between vitamin D sufficiency and 
Anti-CBir1 positivity remained significant when the patients 
were stratified by age group (P = 0.005) (Table 3).
Anti-outer membrane C (Anti-OmpC) and Anti-
saccharomyces cerevisiae antibody (ASCA)
Anti-OmpC and ASCA IgA/IgG were positive in only 
a small number of our pediatric UC patients, 5% and 2%, 
respectively.
DISCUSSION
In our large, rigorously phenotyped inception cohort of 
children with UC, we have shown that 65% of children newly 
diagnosed with UC have a positive pANCA titer. This is simi-
lar to the rate of pANCA positivity in adults, which has been 
shown to be 60%–65%10–12, 24–28. We also demonstrated in our 
TABLE 1: Demographic and Clinical Features of Study Population
All patients N = 399 4–6 years N = 25 7–10 years N = 65 11–13 years N = 111 14–17 years N = 198 P
Age years, mean (SD) 12.7 ± 3.3
Gender (% female) 198 (50%) 15 (60%) 43 (66%) 54 (49%) 86 (43%) 0.010
Non-white race 66/391 (17%) 6/25 (24%) 14/60 (23%) 15/109 (14%) 31/197 (16%) 0.29b
Hispanic 36/395 (9%) 2/24 (8%) 10/65 (15%) 6/110 (5%) 18/196 (9%) 0.17b
Family History of IBD 0.13b
 None 335 (84%)  20 (80%) 56 (86%) 96 (86%) 163 (82%)
UC only 40 (10%) 0 6 (9%) 12 (11%) 22 (11%)
CD only 13 (3%) 3 (12%) 2 (3%) 2 (2%) 6 (3%)
 Mixed 11 (3%) 2 (8%) 1 (2%) 1 (1%) 7 (4%)
BMI Z-score -0.2 ± 1.3 -0.2 ± 1.2 -0.5 ± 1.4 -0.2 ± 1.3 -0.2 ± 1.3 0.26
Proctosigmoiditis 24 (6%) 1 (4%) 4 (6%) 6 (5%) 13 (7%) 0.37
Left-sided colitis 41 (10%) 2 (8%) 5 (8%) 8 (7%) 26 (13%)
Extensive /Pancolitisa 334 (84%) 22 (88%) 56 (86%) 97 (87%) 159 (80%)
PUCAI, mean (SD) 49.9 ± 19.9 44.4 ± 21.3 51.8 ± 20.4 50.3 ± 19.1 49.8 ± 20.1 0.47
PUCAI 10–30 95 (24%) 9 (36%) 13 (20%) 26 (23%) 47 (24%) 0.49
 35–60 172 (43%) 9 (36%) 27 (42%) 47 (42%) 89 (45%)
 ≥65 132 (33%) 7 (28%) 25 (38%) 38 (34%) 62 (31%)
Mayo Endoscopy score 0.32
Grade 1 53 (13%) 5 (20%) 9 (14%) 13 (12%) 26 (13%)
Grade 2 210 (53%) 14 (56%) 37 (57%) 54 (49%) 105 (53%)
Grade 3 136 (34%) 6 (24%) 19 (29%) 44 (40%) 67 (34%)
Hospitalized at baseline 154 (39%) 9 (36%) 28 (43%) 47 (42%) 70 (35%) 0.54
aExtensive/Pancolitis/Unassessable due to severity of disease were all included in this group.
bFisher exact test comparing age groups.
pediatric population that there is an association between high 
titer pANCA (≥100) and more extensive disease; yet, interest-
ingly, we found that the PUCAI and Mayo endoscopic sub-
scores were not significantly different between high and low 
titer pANCA groups. Previous studies have shown that pANCA 
titers can be used to risk stratify patients into immunologically 
distinct subgroups20. In a pediatric study from 1998, Ruemmele 
et al observed differences in the titer of pANCA within sub-
groups of IBD, with equivalently high titers in UC-like CD 
with pancolitis (median of 68.2 EU/mL) and UC (median of 
57.7 EU/mL)9. This stratification by pANCA titer has been 
further explored in adult UC, with Fleshner et al showing that 
a pre-operative pANCA >100 titer was a risk factor for the 
development of chronic pouchitis after ileal pouch-anal anas-
tomosis23 and White et al reporting an association between high 
titer pANCA and both pancolitis and backwash ileitis29. Our 
observed association of higher pANCA titer with more exten-
sive endoscopic disease activity corroborates this relationship 
between magnitude of immune reactivity and extent of disease 
activity.
Beyond phenotypic predictions, pANCA titers have been 
linked to response to therapy. Importantly, Sandborn et  al 
showed in a 1996 retrospective study of 56 UC patients with 
left-sided disease that those who were pANCA-positive were 
more likely to have treatment-resistant disease (90% vs 62%)30. 
And in a larger 2007 study of 100 IBD patients starting inflix-
imab (IFX) therapy, it was confirmed that patients who were 
pANCA+/ASCA− had lower early clinical response—55% 
vs 76% 31. In children, Dubinsky et  al in 2010 reported that 
pANCA positivity is independently associated with primary 
nonresponse to anti-TNFα therapy in both CD and UC (odds 
ratio [OR]: 5.4; P = 0.01) 32. Subsequent long-term analysis of 
the PROTECT cohort will be required to determine if  a rela-
tionship exists between pANCA titer and response to various 
therapies and ultimate outcomes.
Unlike pANCA, the microbial antibodies, ASCA, Anti-
OmpC, and Anti-CBir1 are more common in CD than UC 
with prevalence in CD of 34%–76%, 17%–24%, and 55%–
56%, respectively13, 25, 33, 34. Our data confirmed that antibodies 
to ASCA and Anti-OmpC are uncommon in pediatric UC. 
Importantly, although Anti-CBir1 reactivity is negatively asso-
ciated with UC in adults35, 36, 19% of our population was Anti-
CBir1-positive. This might raise suspicion about the diagnosis 
of UC in our study population; however, observation of the 
study cohort for 1 to 3 years has resulted in no change in diag-
nosis of any of the study patients, suggesting that Anti-CBir is 
more common in pediatric UC than previously appreciated. In 
part, this might be due to the fact that Anti-CBir1 reactivity is 
more common with younger age, as demonstrated now in our 
pediatric UC cohort and previously in pediatric CD13.
From a phenotypic perspective, Anti-CBir1 reactivity 
was associated with rectal sparing, more limited disease extent, 
lower frequency of basal plasmacytosis on rectal biopsy, and 
lower fecal calprotectin. Spiliadis et  al in 1987 were the first 
group to report 12 UC patients with relative endoscopic rec-
tal sparing from their 27-year experience37. Glickman et al in 
2004 described that histologically patchy disease and relative 
rectal sparing occurred in 21% and 26%, respectively, of 73 
pediatric UC patients; interestingly, they also had a compari-
son group of adults that had neither rectal sparing nor patchy 
disease. In this same group, another 16% had only very sub-
tle histologic findings of chronic inflammation38, supporting 
a prior study by Washington et  al, who showed no evidence 
of crypt architectural distortion in 34% of biopsies in new-on-
set UC39. Rajwal et al reported that, in general, relative rectal 
sparing is more common in those younger than 10 years old40. 
This is compatible with our observations that Anti-CBir1 was 
associated with younger age, as well as relative-rectal sparing. 
It is unclear as to whether there are prognostic implications of 
rectal sparing as it relates to therapeutic response or surgical 
FIGURE 1. Relationship of serologic reactivity and age in children newly diagnosed with UC. Bars represent 95% confidence intervals for the percent 
seropositive per age category.
outcomes. Additionally, the CBir1 antigen has a high degree of 
homology to bacterial flagellins, resembling those from enteric 
microbiota including Butyrivibrio, Roseburia, Thermotoga, 
and Clostridium species20. Further examination of Anti-CBir1, 
in conjunction with microbiome data, is warranted.
Lower levels of the damage-associated molecular pattern 
proteins S100A8/S100A9, collectively called fecal calprotectin, 
in the Anti-CBir1-positive group might be explained by the 
relationship between the innate and adaptive immune system. 
Fecal calprotectin mediates a number of different antimicro-
bial functions, and since some patients are low fecal calprotec-
tin expressers, this could theoretically lead to mitigation of the 
microbiota adherent to the mucosa and altered triggering of 
Anti-CBir1 antibodies17, 25, 34.
The relationship between higher, more often sufficient 
levels of  25-OH vitamin D and Anti-CBir1-positive serolo-
gies is intriguing. It is recognized that vitamin D is an impor-
tant component of  both the innate and adaptive immune 
TABLE 2: Relationship of pANCA to Clinical and Laboratory Features in Children Newly Diagnosed with UC
pANCA- pANCA+
P
pANCA + and 
< 100 pANCA ≥ 100
P comparing 
pANCA-, <100, 
≥100N = 139 N = 260 N = 184 N = 76
Age, mean (SD) 12.5 ± 3.6 12.8 ± 3.1 0.29 12.7 ± 3.2 13.1 ± 2.8 0.41
pANCA (%) stratified by age 
categories
— — 0.22 — — 0.26
 4–6 14/25 (56%) 11/25 (44%) 0.022 10/25 (40%) 1/25 (4%) 0.03b
 7–10 20/65 (31%) 45/65 (69%) — 31/65 (48%) 14/65 (22%) —
 11–13 41/111 (37%) 70/111 (63%) — 49/111 (44%) 21/111 (19%) —
 14–17 64/198 (32%) 134/198 (68%) — 94/198 (47%) 40/198 (20%) —
Disease extent (%) — — 0.60 — — 0.004
 Proctosigmoiditis 12 (9%) 12 (5%) — 11 (6%) 1 (1%) —
Left-sided colitis 12 (9%) 29 (11%) — 27 (15%) 2 (3%) —
Extensive /Pancolitisa 115 (83%) 219 (84%) — 146 (79%) 73 (96%) —
PUCAI, mean (SD) 48.3 ± 20.6 50.8 ± 19.6 0.23 50.6 ± 20.1 51.4 ± 18.3 0.45
PUCAI score (%) — — 0.24 — — 0.47
 10–30 41 (29%) 54 (21%) — 39 (21%) 15 (20%) —
 35–60 53 (38%) 119 (46%) — 81 (44%) 38 (50%) —
 ≥65 45 (32%) 87 (33%) — 64 (35%) 23 (30%) —
Mayo Endoscopic Sub-score 
(%)
— — 0.50 — — 0.55
Grade 1 23 (17%) 30 (12%) — 21 (11%) 9 (12%) —
Grade 2 69 (50%) 141 (54%) — 104 (57%) 37 (49%) —
Grade 3 47 (34%) 89 (34%) — 59 (32%) 30 (39%) —
Relative rectal sparing (%) 13/139 (9%) 23/259 (9%) 0.88 13/183 (7%) 10/76 (13%) 0.30
Basal plasmacytosis (%) 56/111 (50%) 112/210 (53%) 0.62 74/151 (49%) 38/59 (64%) 0.12
Hgb (g/dL) N = 130 N = 246 0.59 N = 176 N = 70 0.53
Mean (SD) 11.5 ± 2.4 11.4 ± 2.1 — 11.5 ± 2.1 11.2 ± 2.1 —
ESR (mm/hr) N = 126 N = 236 0.043 N = 170 N = 66 —
Median (IQR) 22 (11, 35) 26 (12, 47) — 23 (11,41) 34 (22,55) <0.0001
Albumin (g/dL) N = 139 N = 258 0.39 N = 182 N = 76
Mean (SD) 3.7 ± 0.7 3.6 ± 0.7 3.7 ± 0.7 3.6 ± 0.7 0.43
Calprotectin (mcg/g) N = 82 N = 146 0.20 N = 108 N = 38 —
Median (IQR) 2023 (1083,3975) 2676 (1378,3928) — 2932 (1414,4036) 1754 (1088,3544) 0.17
CRP or hsCRP (%) N = 103 N = 192 — N = 142 N = 50 —
>ULN 40 (39%) 92 (48%) 0.13 63 (44%) 29 (58%) 0.08
>2xULN 27 (26%) 64 (33%) 0.21 45 (32%) 19 (38%) 0.32
CBir1 positive (%) 33 (24%) 44 (17%) 0.10 28 (15%) 16 (21%) 0.14
aExtensive/Pancolitis /Unassessable due to severity of disease were all included in this group. b Comparison of pANCA for age <7 vs age ≥7.
systems. Immune cells produce both the vitamin D recep-
tor (VDR) and the enzymes to convert vitamin D3 into its 
active 1,25(OH)2D3 form, and this active form can modu-
late numerous cell types, including activated T- and B-cells, 
macrophages, and dendritic cells, leading to an observed anti-
microbial effect41, 42. Additionally, vitamin D affects intesti-
nal barrier function, and VDR-/- mice have been observed to 
have disruptions in their tight junctions, leading to increased 
TABLE 3: Relationship of CBir1 to clinical and laboratory features of children newly diagnosed with UC
CBir1+ N = 77 CBir1- N = 322 P 
Age, mean (SD) 10.9 ± 3.6 13.1 ± 3.1 <0.0001
CBIR (%) stratified by age categories <0.0001
 4–6 11/25 (44%) 14/25 (56%) —
 7–10 21/65 (32%) 44/65 (68%) —
 11–13 25/111 (23%) 86/111 (77%) —
 14–17 20/198 (10%) 178/198 (90%) —
Disease extent (%) 0.041
 Proctosigmoiditis 0 (0%) 24 (7%) —
Left-sided colitis 7 (9%) 34 (11%) —
Extensive /Pancolitisa 70 (91%) 264 (82%) —
PUCAI, mean (SD) 45.7 ± 21.4 51.0 ± 19.4 0.052
PUCAI score (%) 0.095
 10–30 25 (32%) 70 (22%) —
 35–60 30 (39%) 142 (44%) —
 ≥65 22 (29%) 110 (34%) —
Mayo Endoscopic Sub-score (%)
Grade 1 13 (17%) 40 (12%) 0.18
Grade 2 42 (55%) 168 (52%) —
Grade 3 22 (29%) 114 (35%) —
Relative rectal sparing (%) 12/76 (16%) 24/322 (7%) 0.023
Basal plasmacytosis (%) 22/58 (38%) 146/263 (56%) 0.015
Hgb (g/dL) 11.0 ± 2.2 11.5 ± 2.2 0.063
Mean (SD) N = 75 N = 301 —
ESR (mm/hr) 25 (16, 49) 24 (12, 40) 0.33
Median (IQR) N = 70 N = 292 —
Albumin (g/dL) 3.7 ± 0.8 3.6 ± 0.7 0.26
Mean (SD) N = 77 N = 320
Calprotectin (mcg/g) 1495 (971, 3333) 2634 (1324, 4022) 0.046
Median (IQR) N = 35 N = 193 —
CRP or hsCRP (%)
>ULN 24 (44%) 108 (45%) 0.85
>2xULN 17 (31%) 74 (31%) 0.99
N = 55 N = 240 —
25-OH Vitamin D (ng/mL) 30.9 (27.2,38.0) 27.6 (23.0,33.4) 0.0002
Median (IQR) N = 75 N = 317 —
25-OH Vitamin D (%) — — 0.0009
<20 Deficient 5 (7%) 37 (12%) —
20-< 30 Insufficient 25 (33%) 159 (50%) —
≥30 Sufficient 45 (60%) 121 (38%) 0.005b
pANCA positive (%) 44 (57%) 216 (67%) 0.10
aExtensive/Pancolitis /Unassessable due to severity of disease were all included in this group.
bP value for association of CBir1 with 25-OH vitamin D ≥30 stratified by age-group based on a Mantel-Haenszel χ2 test.
susceptibility to DSS injury43. It is possible that vitamin D 
mediates the immune response in such a way that alters the 
adaptive anti-flagellin response, leading to production of 
Anti-CBir1.
Our study has several limitations. Due to its multicenter 
nature, there may have been site-specific differences in clinical 
scoring despite prespecified guidelines in the PROTECT study 
protocol. Mayo endoscopy su-scores were guided at each site by 
standardized photographs. Histologic examination was done 
by a central reader (MHC). There was also a larger acceptable 
window for attaining baseline labs, which included the serolog-
ical assessment, before treatment in those with mild disease (8 
weeks vs 4 weeks); however, it is unlikely that there would have 
been large shifts in titers in this mild population over this short 
interval. Given the exploratory nature of our study, unadjusted 
P values were used.
In summary, our study greatly extends the knowledge 
base of serologic expression in children with UC. Future work 
will be required to examine the relationship of serologic reac-
tivity to colonic community microbial profiling as well as rectal 
gene expression. These relationships may provide a platform to 
better understand disease pathogenesis and perhaps response 
to therapy.
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